Unknown

Dataset Information

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports.


ABSTRACT:

Rationale

Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice.

Patient concerns

Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma.

Diagnosis

They were diagnosed as refractory nasopharyngeal carcinoma.

Interventions

A continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients.

Outcomes

Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein-Barr virus (EBV) DNA load.

Lessons

Continuous infusions of En

SUBMITTER: Chen C 

PROVIDER: S-EPMC6709293 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature